Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
<h4>Background</h4>The RV144 clinical trial showed for the first time that vaccination could provide modest but significant protection from HIV-1 infection. To understand the protective response, and to improve upon the vaccine's efficacy, it is important to define the structure of the immunogens us...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Public Library of Science (PLoS)
2012-01-01
|
| Edice: | PLoS ONE |
| On-line přístup: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22928048/pdf/?tool=EBI |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|